High-throughput screening for new drugs | AltAssets Private Equity News

Subscribe today

Advanced
Search

High-throughput screening for new drugsp

23 Apr 2003

High-throughput testing of potential drug candidates for specific biological activity has been gaining importance in the drug discovery process since the 1980s. Dr Dan Gelvan, chief executive officer of Zetiq Technologies examines the latest trends in this area and discusses the activities of some of the key corporate players.

Sorry, to read the full story you must be a Premium Subscriber

Are you a subscriber?

In order to view premium content you need to be a Premium Subscriber. You can subscribe now to access premium online content.

Become a Premium Subscriber
for only £150 / €180 / $225 p.a.

Login area

If you are already a AltAssets subscriber please log in below.